iRadimed (NASDAQ:IRMD) Hits New 52-Week High – Still a Buy?
by Tristan Rich · The Markets DailyiRadimed Corporation (NASDAQ:IRMD – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $103.11 and last traded at $102.7660, with a volume of 38362 shares traded. The stock had previously closed at $102.00.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the stock. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Finally, Roth Capital set a $90.00 target price on iRadimed in a research note on Friday, October 31st. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.33.
Check Out Our Latest Report on IRMD
iRadimed Price Performance
The company has a market cap of $1.31 billion, a price-to-earnings ratio of 62.41 and a beta of 1.09. The firm has a 50-day moving average price of $94.73 and a 200 day moving average price of $78.78.
iRadimed (NASDAQ:IRMD – Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. The business had revenue of $21.20 million during the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, equities analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current fiscal year.
iRadimed Dividend Announcement
The business also recently disclosed a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were paid a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is 41.21%.
Insiders Place Their Bets
In other iRadimed news, CFO John Glenn sold 15,000 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the sale, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $97.45, for a total value of $487,250.00. Following the completion of the sale, the chief executive officer directly owned 2,272,500 shares in the company, valued at $221,455,125. This trade represents a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 55,000 shares of company stock worth $5,077,100 in the last 90 days. 36.80% of the stock is owned by company insiders.
Institutional Trading of iRadimed
Hedge funds have recently made changes to their positions in the company. CWM LLC grew its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP acquired a new position in shares of iRadimed in the third quarter worth approximately $40,000. Tower Research Capital LLC TRC lifted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 495 shares during the period. State of Alaska Department of Revenue bought a new stake in iRadimed in the third quarter valued at approximately $47,000. Finally, Spire Wealth Management acquired a new stake in iRadimed during the 2nd quarter valued at approximately $60,000. 92.34% of the stock is owned by institutional investors and hedge funds.
iRadimed Company Profile
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.